Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

A. Rizzo, V. Mollica, A. Marchetti, G. Nuvola, M. Rosellini, E. Tassinari, J. Molina-Cerrillo, ZW. Myint, T. Buchler, FSM. Monteiro, E. Grande, M. Santoni, F. Massari

. 2022 ; 14 (17) : . [pub] 20220826

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023434

BACKGROUND: Adjuvant treatment has always been a cornerstone in the therapeutic approach of many cancers, considering its role in reducing the risk of relapse and, in some cases, increasing overall survival. Adjuvant immune checkpoint inhibitors have been tested in different malignancies. METHODS: We performed a meta-analysis aimed to explore the impact of adjuvant PD-1 and PD-L1 inhibitors on relapse-free survival (RFS) in cancer patients enrolled in randomized controlled clinical trials. We retrieved all phase III trials published from 15 June 2008 to 15 May 2022, evaluating PD-1/PD-L1 inhibitors monotherapy as an adjuvant treatment by searching on EMBASE, Cochrane Library, and PubMed/ Medline, and international oncological meetings' abstracts. The outcome of interest was RFS. We also performed subgroup analyses focused on age and gender. RESULTS: Overall, 8 studies, involving more than 6000 patients, were included in the analysis. The pooled results highlighted that the use of adjuvant PD-1/PD-L1 inhibitors may reduce the risk of relapse compared to control treatments (hazard ratio, 0.72; 95% confidence intervals, 0.67-0.78). In addition, the subgroup analyses observed that this benefit was consistent in different patient populations, including male, female, younger, and older patients. CONCLUSIONS: Adjuvant anti-PD-1/PD-L1 treatment is associated with an increased RFS in the overall population and in subgroups divided according to age and gender.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023434
003      
CZ-PrNML
005      
20221031095210.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14174142 $2 doi
035    __
$a (PubMed)36077679
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rizzo, Alessandro $u Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Istituto Tumori Giovanni Paolo II-Bari, Viale Orazio Flacco 65, 70124 Bari, Italy $1 0000000252578678
245    10
$a Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study / $c A. Rizzo, V. Mollica, A. Marchetti, G. Nuvola, M. Rosellini, E. Tassinari, J. Molina-Cerrillo, ZW. Myint, T. Buchler, FSM. Monteiro, E. Grande, M. Santoni, F. Massari
520    9_
$a BACKGROUND: Adjuvant treatment has always been a cornerstone in the therapeutic approach of many cancers, considering its role in reducing the risk of relapse and, in some cases, increasing overall survival. Adjuvant immune checkpoint inhibitors have been tested in different malignancies. METHODS: We performed a meta-analysis aimed to explore the impact of adjuvant PD-1 and PD-L1 inhibitors on relapse-free survival (RFS) in cancer patients enrolled in randomized controlled clinical trials. We retrieved all phase III trials published from 15 June 2008 to 15 May 2022, evaluating PD-1/PD-L1 inhibitors monotherapy as an adjuvant treatment by searching on EMBASE, Cochrane Library, and PubMed/ Medline, and international oncological meetings' abstracts. The outcome of interest was RFS. We also performed subgroup analyses focused on age and gender. RESULTS: Overall, 8 studies, involving more than 6000 patients, were included in the analysis. The pooled results highlighted that the use of adjuvant PD-1/PD-L1 inhibitors may reduce the risk of relapse compared to control treatments (hazard ratio, 0.72; 95% confidence intervals, 0.67-0.78). In addition, the subgroup analyses observed that this benefit was consistent in different patient populations, including male, female, younger, and older patients. CONCLUSIONS: Adjuvant anti-PD-1/PD-L1 treatment is associated with an increased RFS in the overall population and in subgroups divided according to age and gender.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy $u Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, 40138 Bologna, Italy $1 0000000251693631
700    1_
$a Marchetti, Andrea $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy $1 0000000178929619
700    1_
$a Nuvola, Giacomo $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy $1 0000000294985466
700    1_
$a Rosellini, Matteo $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy $1 0000000249209951
700    1_
$a Tassinari, Elisa $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
700    1_
$a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, 28034 Madrid, Spain $1 0000000346160598
700    1_
$a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0293, USA $1 0000000234794203
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, 14059 Prague, Czech Republic $1 000000016667994X
700    1_
$a Monteiro, Fernando Sabino Marques $u Hospital Santa Lucia, Brasilia 70390-700, Brazil $u Hospital Universitário de Brasilia, Brasilia 70840-901, Brazil $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre 90619-900, Brazil $1 0000000266218251
700    1_
$a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, 28033 Madrid, Spain $1 0000000201344732
700    1_
$a Santoni, Matteo $u Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, Italy
700    1_
$a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy $u Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, 40138 Bologna, Italy $1 0000000164766871
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 17 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36077679 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095207 $b ABA008
999    __
$a ind $b bmc $g 1853865 $s 1174722
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 17 $e 20220826 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Možnosti archivace